Last update 17 Dec 2024

Levothyroxine Sodium

Overview

Basic Info

SummaryLevothyroxine Sodium is a fascinating small molecule drug that acts as a synthetic version of the thyroid hormone and targets the thyroid hormone receptor as a thyroid hormone agonist. Its wide range of uses is impressive, as it is used to treat hypothyroidism, hyperthyroidism, goiter, and hyperpituitarism. Hypothyroidism, a condition characterized by the thyroid gland's inability to produce enough thyroid hormone, is effectively treated with this drug, while hyperthyroidism, a condition marked by excessive production of thyroid hormone, is also targeted by Levothyroxine Sodium. Goiter, or the enlargement of the thyroid gland, and hyperpituitarism, or the overactivity of the pituitary gland, can also be treated using this drug. AbbVie was the trailblazing organization behind this drug, and it was initially approved for medical use in 1964, impressing healthcare providers ever since.
Drug Type
Small molecule drug
Synonyms
Levothyroxine Sodium Hydrate, LT4, Sustained-release levothyroxine sodium
+ [29]
Target
Mechanism
THR agonists(Thyroid hormone receptor agonists)
Inactive Indication-
Originator Organization
Drug Highest PhaseApproved
First Approval Date
JP (07 Aug 1964),
Regulation-
Login to view timeline

Structure

Molecular FormulaC15H13I4NNaO5
InChIKeyVSGRWOHSMUGJIF-LTCKWSDVSA-N
CAS Registry6106-07-6

External Link

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Differentiated Thyroid Gland Carcinoma
US
29 Apr 2022
Myxedema coma
US
24 Jun 2011
Hyperpituitarism
US
25 May 2001
Hyperthyroidism
CN
01 Jan 2000
Thyroid Cancer
CN
01 Jan 2000
Goiter
JP
12 Feb 1998
Myxedema
JP
12 Feb 1998
Congenital Hypothyroidism
JP
07 Sep 1994
Hypothyroidism
JP
07 Aug 1964
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
13
(Single Therapy)
hbrwtwbojg(nglsenzpch) = cuvefoogsy ofmdqqejnf (nquuopdydc, rrellfsehq - pjmxellzcu)
-
14 Jun 2024
(Combination Therapy)
hbrwtwbojg(nglsenzpch) = voctqlvtem ofmdqqejnf (nquuopdydc, rldjnitmhh - jovetwmbmc)
Phase 2
46
gieugdwobt(vfpnevoepd) = wqyfheepou pftdlanfqy (ilgdvkzzhs )
Positive
30 May 2024
Not Applicable
-
(Control group (PBS))
wmcsmrwkve(mlfzaedehg) = sooferrdmp udejpmaewh (jvpadknsia )
-
19 May 2024
(Treatment group (T3))
wmcsmrwkve(mlfzaedehg) = noosprzitj udejpmaewh (jvpadknsia )
Not Applicable
Metastatic Colorectal Carcinoma
First line
RAS wild type | RAS mutated | BRAF mutant
139
ysgbmiemlc(hvgeeaajbj) = jqatbjskxo sarutisxyf (iwpdzwwtlx )
Negative
01 Jul 2023
ysgbmiemlc(hvgeeaajbj) = jqbzxwxaxz sarutisxyf (iwpdzwwtlx )
Phase 4
66
(Tirosint Capsules)
dwgbeuucts(wnagvffypg) = btgrbodcmx jccsmhrclj (ukrorszqci, ubqnhdnrvs - dkqxopkehw)
-
05 Apr 2022
(Treatment Period: Tirosint Capsules)
mlbuloadfr(hbjrbndrnr) = fxvnnggxvc rbgmaqhafn (jgqtourovz, hbqyqtsqjy - egcgyvifrw)
Phase 4
669
hpkvbjwrby(lnjyprczbw) = klmggavavg zbvazgplyw (gswbgpateo, -0.16 to 0.11)
-
26 Feb 2022
Not Applicable
-
vzrkryenfy(zmqigezmzl): adjusted odds ratio = 1.36 (95% CI, 1.01 - 1.83), P-Value = 0.04
-
01 Jan 2022
No L-T4 treatment
Not Applicable
-
L-T4 1.5 mg/kg/day
uscxwfbezr(tcsoqciiwn) = euznhkijie tcnobiwntn (ennhkevzsm )
-
22 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free